Judith Christina Maro, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Product Surveillance, Postmarketing | 13 | 2023 | 430 | 4.660 |
Why?
|
Herpes Zoster Vaccine | 3 | 2023 | 47 | 2.320 |
Why?
|
Herpes Zoster | 3 | 2023 | 264 | 2.010 |
Why?
|
Pharmacoepidemiology | 5 | 2022 | 323 | 1.970 |
Why?
|
Data Mining | 8 | 2023 | 537 | 1.010 |
Why?
|
Adverse Drug Reaction Reporting Systems | 6 | 2023 | 469 | 0.990 |
Why?
|
United States Food and Drug Administration | 12 | 2023 | 1584 | 0.920 |
Why?
|
Guillain-Barre Syndrome | 2 | 2022 | 120 | 0.870 |
Why?
|
Databases, Factual | 12 | 2022 | 7729 | 0.810 |
Why?
|
Urticaria | 1 | 2022 | 150 | 0.790 |
Why?
|
Papillomavirus Vaccines | 3 | 2021 | 491 | 0.710 |
Why?
|
Vaccination | 6 | 2023 | 3278 | 0.680 |
Why?
|
Pain, Intractable | 1 | 2020 | 130 | 0.680 |
Why?
|
Vaccines, Attenuated | 2 | 2019 | 342 | 0.660 |
Why?
|
Food | 1 | 2023 | 771 | 0.640 |
Why?
|
Exanthema | 1 | 2022 | 501 | 0.620 |
Why?
|
Sentinel Surveillance | 4 | 2018 | 281 | 0.610 |
Why?
|
Propensity Score | 6 | 2022 | 1781 | 0.610 |
Why?
|
Vaccines | 3 | 2014 | 822 | 0.590 |
Why?
|
Research Design | 3 | 2022 | 5987 | 0.550 |
Why?
|
Dermatitis, Atopic | 1 | 2022 | 654 | 0.530 |
Why?
|
Drug Approval | 2 | 2020 | 742 | 0.520 |
Why?
|
Drug Interactions | 1 | 2020 | 1460 | 0.520 |
Why?
|
Myocarditis | 1 | 2022 | 771 | 0.510 |
Why?
|
Insurance Claim Review | 1 | 2019 | 720 | 0.510 |
Why?
|
Papillomavirus Infections | 3 | 2021 | 1587 | 0.480 |
Why?
|
Orphan Drug Production | 1 | 2014 | 50 | 0.470 |
Why?
|
Drug Monitoring | 1 | 2019 | 956 | 0.440 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 850 | 0.430 |
Why?
|
Models, Immunological | 1 | 2014 | 527 | 0.420 |
Why?
|
Pregnancy Outcome | 1 | 2022 | 2795 | 0.420 |
Why?
|
Risk | 4 | 2019 | 9687 | 0.400 |
Why?
|
International Classification of Diseases | 3 | 2021 | 867 | 0.400 |
Why?
|
Computer Communication Networks | 3 | 2020 | 295 | 0.390 |
Why?
|
Influenza, Human | 3 | 2023 | 1479 | 0.390 |
Why?
|
Data Collection | 1 | 2020 | 3341 | 0.380 |
Why?
|
Warfarin | 1 | 2019 | 1496 | 0.370 |
Why?
|
Rare Diseases | 1 | 2014 | 553 | 0.350 |
Why?
|
Seizures | 2 | 2019 | 2859 | 0.340 |
Why?
|
Incidence | 6 | 2021 | 20947 | 0.300 |
Why?
|
United States | 19 | 2023 | 69872 | 0.290 |
Why?
|
Pharmaceutical Preparations | 3 | 2023 | 1071 | 0.260 |
Why?
|
Sample Size | 2 | 2022 | 845 | 0.260 |
Why?
|
Cohort Studies | 8 | 2023 | 40561 | 0.260 |
Why?
|
Computer Simulation | 3 | 2014 | 6196 | 0.250 |
Why?
|
Registries | 2 | 2022 | 8089 | 0.230 |
Why?
|
Analgesics, Opioid | 1 | 2020 | 3674 | 0.230 |
Why?
|
Papillomaviridae | 2 | 2021 | 1119 | 0.230 |
Why?
|
Models, Statistical | 3 | 2014 | 5102 | 0.220 |
Why?
|
Medical Records Systems, Computerized | 1 | 2009 | 1205 | 0.220 |
Why?
|
Humans | 42 | 2023 | 744343 | 0.210 |
Why?
|
Herpesvirus 3, Human | 1 | 2023 | 204 | 0.200 |
Why?
|
Health Services Research | 1 | 2009 | 1836 | 0.200 |
Why?
|
Losartan | 1 | 2023 | 299 | 0.190 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2023 | 139 | 0.190 |
Why?
|
Oxymorphone | 1 | 2020 | 7 | 0.190 |
Why?
|
Electronic Health Records | 6 | 2023 | 4468 | 0.180 |
Why?
|
Data Interpretation, Statistical | 2 | 2021 | 2716 | 0.180 |
Why?
|
Drug Evaluation | 1 | 2021 | 647 | 0.180 |
Why?
|
Decision Making, Organizational | 1 | 2020 | 139 | 0.170 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 634 | 0.170 |
Why?
|
Incretins | 1 | 2019 | 88 | 0.170 |
Why?
|
Stillbirth | 1 | 2022 | 346 | 0.170 |
Why?
|
Software | 2 | 2018 | 4443 | 0.160 |
Why?
|
Oxycodone | 1 | 2020 | 153 | 0.160 |
Why?
|
Live Birth | 1 | 2022 | 512 | 0.160 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2018 | 113 | 0.150 |
Why?
|
Time Factors | 6 | 2021 | 40075 | 0.150 |
Why?
|
Myocardial Infarction | 1 | 2019 | 11727 | 0.150 |
Why?
|
Hypoglycemic Agents | 2 | 2019 | 2872 | 0.150 |
Why?
|
Pandemics | 3 | 2021 | 8388 | 0.150 |
Why?
|
Technology | 1 | 2019 | 305 | 0.150 |
Why?
|
Diabetic Ketoacidosis | 1 | 2019 | 245 | 0.140 |
Why?
|
Cluster Analysis | 1 | 2022 | 2715 | 0.130 |
Why?
|
Medical Records | 1 | 2019 | 1413 | 0.120 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2021 | 1381 | 0.120 |
Why?
|
Seizures, Febrile | 1 | 2014 | 111 | 0.110 |
Why?
|
Pancreatitis | 1 | 2019 | 1092 | 0.110 |
Why?
|
Algorithms | 5 | 2021 | 13881 | 0.100 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 367 | 0.090 |
Why?
|
Poisson Distribution | 1 | 2011 | 513 | 0.090 |
Why?
|
Electronics | 2 | 2022 | 322 | 0.090 |
Why?
|
Pilot Projects | 2 | 2020 | 8324 | 0.090 |
Why?
|
Anticonvulsants | 1 | 2019 | 1916 | 0.090 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2014 | 373 | 0.090 |
Why?
|
Anaphylaxis | 1 | 2015 | 746 | 0.080 |
Why?
|
Influenza Vaccines | 1 | 2015 | 738 | 0.080 |
Why?
|
Kidney Diseases | 1 | 2019 | 2149 | 0.080 |
Why?
|
Observation | 1 | 2009 | 312 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2208 | 0.070 |
Why?
|
Monte Carlo Method | 1 | 2011 | 1254 | 0.070 |
Why?
|
Canada | 2 | 2023 | 2065 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1671 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12354 | 0.070 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2018 | 2020 | 0.070 |
Why?
|
Financing, Government | 1 | 2009 | 468 | 0.070 |
Why?
|
Young Adult | 6 | 2021 | 56430 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2019 | 3336 | 0.060 |
Why?
|
Risk Assessment | 2 | 2019 | 23338 | 0.060 |
Why?
|
Logistic Models | 1 | 2019 | 13408 | 0.060 |
Why?
|
Female | 10 | 2022 | 380194 | 0.060 |
Why?
|
Pregnancy | 2 | 2022 | 29144 | 0.060 |
Why?
|
HIV Infections | 2 | 2020 | 16718 | 0.060 |
Why?
|
Adolescent | 6 | 2021 | 85781 | 0.060 |
Why?
|
Prospective Studies | 4 | 2021 | 53288 | 0.060 |
Why?
|
Hypertension | 1 | 2023 | 8480 | 0.050 |
Why?
|
Infant | 2 | 2022 | 35136 | 0.050 |
Why?
|
Treatment Outcome | 2 | 2021 | 63114 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10262 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 3022 | 0.050 |
Why?
|
Denmark | 1 | 2023 | 738 | 0.050 |
Why?
|
Decision Making | 1 | 2014 | 3887 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2019 | 19905 | 0.050 |
Why?
|
Biological Therapy | 1 | 2021 | 138 | 0.040 |
Why?
|
Clinical Coding | 1 | 2021 | 171 | 0.040 |
Why?
|
Glycosides | 1 | 2019 | 107 | 0.040 |
Why?
|
Male | 7 | 2021 | 350118 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14722 | 0.040 |
Why?
|
Biphenyl Compounds | 1 | 2023 | 913 | 0.040 |
Why?
|
Adult | 7 | 2021 | 214055 | 0.040 |
Why?
|
Aged | 3 | 2019 | 163280 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15076 | 0.040 |
Why?
|
Child | 3 | 2021 | 77709 | 0.040 |
Why?
|
Tetrazoles | 1 | 2023 | 835 | 0.040 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2023 | 924 | 0.040 |
Why?
|
Fertility | 1 | 2022 | 781 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1518 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 10900 | 0.030 |
Why?
|
Vaccines, Inactivated | 1 | 2015 | 184 | 0.030 |
Why?
|
Middle Aged | 5 | 2019 | 213383 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2021 | 857 | 0.030 |
Why?
|
Immunization | 1 | 2018 | 1256 | 0.030 |
Why?
|
Prevalence | 2 | 2021 | 15226 | 0.030 |
Why?
|
Gestational Age | 1 | 2022 | 3493 | 0.030 |
Why?
|
HIV | 1 | 2020 | 1604 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2018 | 2373 | 0.030 |
Why?
|
Risk Factors | 2 | 2018 | 72290 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2019 | 1041 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 2987 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2661 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 77449 | 0.020 |
Why?
|
Inpatients | 1 | 2018 | 2518 | 0.020 |
Why?
|
Biomedical Research | 1 | 2020 | 3309 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2019 | 4256 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7659 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39050 | 0.010 |
Why?
|
Child, Preschool | 1 | 2015 | 41006 | 0.010 |
Why?
|